RxDoctor Payments Data

Donald Pratt, MD

Internal Medicine · Mission Viejo, CANPI 1437136660

Payments from drug & device makers

$355in general payments, 2019–2025

Across 12 payments — averaging $29.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$140
  • Boehringer Ingelheim$97
  • Boston Scientific$31
  • Otsuka America Pharmaceutical, Inc.$26
  • Sanofi Pasteur Inc.$25
  • Amgen$19
  • plus $17 from 1 others

What the payments were for

  • Consulting fees$257%
  • Food & beverage$33093%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$355 in reported general payments places this provider in the 60th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$99,811
Medicare patients
422
Services billed
1,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban52$74,082
EliquisApixaban58$44,806
JardianceEmpagliflozin24$32,420
FarxigaDapagliflozin Propanediol22$29,237
OzempicSemaglutide24$28,448
EntrestoSacubitril/Valsartan17$19,897
JanuviaSitagliptin Phosphate13$17,779
MyrbetriqMirabegron16$10,536
Valsartan201$8,779
Rosuvastatin Calcium368$6,630
Atorvastatin Calcium584$6,485
SynthroidLevothyroxine Sodium78$5,164
Amlodipine Besylate448$3,641
Tamsulosin Hcl163$3,394
Losartan Potassium309$3,364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$97$32,42024 claims
AstraZenecaFarxiga$140$29,23722 claims
NovartisEntresto$17$19,89717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →